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554Unrelated Donor Hematopoietic Cell Transplantation
for Non-Hodgkin Lymphoma: Long-Term Outcomes
Koen van Besien,1 Jeanette Carreras,2 Philip J. Bierman,3 Brent R. Logan,2
Arturo Molina,4 Roberta King,5 Gene Nelson,5 Joseph W. Fay,6 Richard E. Champlin,7
Hillard M. Lazarus,8 Julie M. Vose,3 Parameswaran N. Hari2We analyzed the outcomes of 283 patients receiving unrelated donor allogeneic hematopoietic cell trans-
plantation for non-Hodgkin lymphoma (NHL) facilitated by the Center for International Blood and Marrow
Transplant Research/National Marrow Donor Program (CIBMTR/NMDP) between 1991 and 2004. All
patients received myeloablative conditioning regimens. The median follow-up of survivors is 5 years.
Seventy-three (26%) patients are alive. The day 100 probability of death from all causes is estimated at
39%. The cumulative incidence of developing grade III-IV acute graft-versus-host disease (aGVHD) at day
100 is 25%. The estimated 5-year survival and failure free survival are 24% (95% confidence interval [CI]:
19-30) and 22% (95% CI: 17-28), respectively. Factors adversely associated with overall survival (OS)
included increasing age, decreased performance status, and refractory disease. Follicular lymphoma (FL)
and peripheral T cell lymphoma had improved survival compared to aggressive B cell lymphomas. Factors
adversely associated with progression-free survival (PFS) included performance status, histology, and disease
status at transplant. Long-term failure-free survival is possible following unrelated donor transplantation for
NHL, although early mortality was high in this large cohort.
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In 1993, the National Marrow Donor Program
(NMDP) reported on 462 patients undergoing unre-
lated donor hematopoietic cell transplantation
(HCT). The large majority of these patients suffered
from leukemia, only 8 patients with lymphoma were
included [1]. Since then, unrelated donor HCT has
become a standard form of treatment for patients
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6/j.bbmt.2009.01.012have permittedmore accurate identification of compat-
ible donor-recipient pairs, and many recent series sug-
gest that the outcomes of HLA-identical unrelated
donor transplantation are virtually identical to that of
HLA-identical sibling transplantation for leukemia
[5-7]. At the same time, allogeneic sibling HCT has
become more widely used in lymphoma. It is widely
accepted as an excellent treatment for relapsed follicu-
lar lymphoma (FL) [8-11], and is often used as an alter-
native to autologous transplant in large cell lymphoma
[12-15], mantle cell lymphoma [16,17], T cell lym-
phoma [18-21], in high-grade lymphomas [22,23], in
patients with lymphoma who have failed prior autolo-
gous transplantation [24]. Unrelated donorHCT is in-
creasingly used in NHL [8,12,16,25-28], and single-
institution studies report similar outcomes after related
and unrelated donor transplantation for lymphoma
[29], but large series are lacking. This report
describes cure rates and treatment complications in
a large patient cohort with very high-risk characteris-
tics undergoing unrelated allogeneic HCT for non-
Hodgkin lymphoma (NHL) facilitated by the
NMDP. Because the large majority of the patients
received total body irradiation (TBI)-based condition-
ing, this dataset does not address questions regarding
relative superiority of various transplant conditioning
regimens.
Table 1. Variables Tested in Cox Proportional Hazards
Regression Models
Patient-related variables:
Age: #20* versus 21-40 versus $40
Sex: male* versus female
Karnofsky performance status: <90%* versus $90%
Disease-related variables
Histology: follicular* versus DLCL/immunoblastic versus lymphoblastic/
Burkitts/Burkitt-like versus mantle cell versus peripheral T cell versus others
Disease status at transplant: chemosensitive CR* versus chemosensitive PR
versus chemoresistant
Treatment-related variables:
Time from diagnosis to transplant: TBD (will look for optimal cutoff point)
TBI conditioning: no* versus yes
T cell depletion: no* versus yes
Type of donor: well-matched* versus others
Donor age: 11-20* years versus 21-30 years versus 31-40 years versus 41-50
years versus 51-60 years
Donor type: well matched versus others
CMV status: +/+ versus +/2 versus 2/+ versus 2/2 versus not tested
Year of transplant: 1991-1994* versus 1995-1999 versus 2000-2004
CR indicates complete remission; PR, partial remission; TBI, total body
irradiation; TBD, to be determined; CMV, cytomegalovirus.
*Reference group.
Table 2. Characteristics of Patients Who Underwent
Matched Unrelated Donor Allogeneic Hematopoietic Stem
Cell Transplant with Myeloablative Conditioning for NHL and
Reported to the CIBMTR between 1991 and 2004
Variable N eval N (%)
Number of patients 283
Number of centers 63
Age, median (range), years 283 37 (2-65)
Age at transplant, years 283
#10 16 (6)
11-20 34 (12)
21-30 62 (22)
31-40 58 (20)
41-50 84 (30)
51-60 27 (9)
$61 2 (1)
Male sex 283 188 (66)
Karnofsky score pretransplant 270
<90 100 (37)
$90 170 (63)
Histology 283
Follicular 62 (22)
DLCL/Immunoblastic 73 (26)
Lymphoblastic/Burkitts/Burkitt-like 68 (24)
Mantle Cell 20 (7)
Peripheral T cell 19 (7)
Others* 41 (14)
Disease status at transplant 269
CR1 41 (15)
CR2+ 30 (11)
PIF resistant 74 (28)
PIF sensitive 57 (21)
REL resistant 27 (10)
REL sensitive 40 (15)
Extranodal sites of disease at transplant 51
1 5 (10)
2 1 (2)
No extranodal involvement 45 (88)
Disease stage at diagnosis 283
I-II 59 (21)
III-IV 206 (73)
Unknown 18 (6)
Interval from diagnosis to transplant, median
(range), months
283 17 (1-192)
Conditioning regimen 283
TBI + Cy ± other 212 (75)
TBI ± other 26 (9)
Bu + Cy ± other 38 (13)
Cy ± other 3 (1)
Others† 4 (2)
Fludarabine 106
Yes 5 (5)
No 101 (95)
T cell depletion‡ 283
Yes 78 (28)
No 205 (72)
Donor age, median (range), years 282 36 (20-54)
Donor age at transplant, years 282
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Data Sources
The Center for International Blood and Marrow
Transplant Research (CIBMTR) is a research affilia-
tion of the International Bone Marrow Transplant
Registry (IBMTR), Autologous Blood and Marrow
Transplant Registry (ABMTR), and the NMDP that
comprises a voluntary working group of more than
450 transplant centers worldwide that contribute
detailed data on consecutive allogeneic and autologous
transplants to a Statistical Center at the Health Policy
Institute of the Medical College of Wisconsin in
Milwaukee or the NMDP Coordinating Center in
Minneapolis. Participating centers are required to
report all consecutive transplants; compliance is mon-
itored by on-site audits. Subjects are followed longitu-
dinally, with yearly follow-up. Computerized checks
for errors, physicians’ review of submitted data, and
on-site audits of participating centers ensure data qual-
ity. Observational studies conducted by the CIBMTR
are done with a waiver of informed consent and in
compliance with HIPAA regulations as determined
by the Institutional Review Board and the Privacy
Officer of the Medical College of Wisconsin.11-20 7 (2)
21-30 76 (27)
31-40 121 (43)
41-50 70 (25)
51-60 8 (3)
Type of donor§ 283
Well-matched 153 (54)
Partially matched 111 (39)
Mismatched 17 (6)
Unknown 2 (1)
Graft type 283
Bone marrow 223 (79)
Peripheral blood 60 (21)
(Continued )Patients
The outcomes of patients with NHL who under-
went myeloablative unrelated allogeneic bone marrow
or peripheral blood HCT facilitated by the NMDP
between 1991 and 2004 are reported. The policies
and procedures of the NMDP have been described
previously [2,3]. All donors signed written statements
of informed consent prior to donation. Patients with
a prior autologous HCT and recipients of cord blood
Table 2. (Continued )
Variable N eval N (%)
Donor-recipient sex match 283
M-M 132 (47)
M-F 57 (20)
F-M 56 (20)
F-F 38 (13)
Donor/recipient CMV status 283
+/+ 31 (11)
+/2 24 (8)
2/+ 82 (29)
2/2 109 (39)
Not tested 37 (13)
GVHD prophylaxis 283
MTX + CsA ± other 127 (45)
CsA ± other 12 (4)
MTX + FK506 ± other 76 (27)
FK506 ± other 12 (4)
T cell depletion ± other 52 (18)
Others§ 4 (2)
Year of transplant 283
1991-1994 11 (4)
1995-1999 114 (40)
2000-2004 158 (56)
Median follow-up of survivors, months 73 61 (8-145)
Follow-up completeness index 5 98%.
NHL indicatesnon-Hodgkin lymphoma;CR, completeremission;CIBMTR,
Center for International Blood and Marrow Transplant Research; Cy,
cyclophosphamide; TBI, total body irradiation; CsA, cyclosporine; GVHD,
graft-versus-host disease; MTX, methotrexate; CMV, cytomegalovirus;
DLCL, diffuse large cell lymphoma; PIF, prolactin release-inhibiting factor;
REL, ring enhancing lesion; Bu, busulfan; MM, multiple myeloma.
*Others histology includes (N 5 41):
1. NHL, not otherwise stated (NOS) (n 5 3)
2. NHL other, not specified (n 5 35)
3. Extranodal marginal zone B cell of MALT (n 5 1)
4. Nodal marginal zone B cell (n 5 2)
† Other conditioning regimen includes (N 5 4):
1. Bu + L-PAM (n 5 2)
2. Carboplatin + Thiotepa + other (n 5 2)
‡ T cell depletion includes:
1. 26 received in vivo T cell depletion with antithymocyte globulin (ATG) or
Campath.
2. 40 grafts were in vitro T cell depleted with various antibody based
methods.
3. 12 grafts were in vitro T cell depleted with antibody based methods
combined with in vivo administration of ATG.
§ Type of donor defined as:
Well-matched includes: 1,7,10,16 (see below)
Partially matched includes: 2,3,8,11,13,21 (see below)
Mismatched includes 5,6,9 (see below)
HLA Groups N
1 Matched 8/8 at high-res HLA-A, -B, -C, and
-DRB1
112
2 Single allele MM (7/8) at high-res HLA-A, -B, -C,
and -DRB1
17
3 Single antigen MM (7/8) at high-res HLA-A, -B,
-C, and -DRB1
26
5 $2 MM with 1 antigen MM (<7/8) at high-res
HLA-A, -B, -C, and -DRB1
13
6 $2 MM with 2 or more antigen MM (<7/8) at
high-res HLA-A, -B, -C and -DRB1
2
7 Matched 8/8 at high-res HLA-A, -B, and -DRB1
and low-res at HLA-C
5
8 Single MM (7/8) at high-res HLA-A, -B, and
-DRB1 and low-res at HLA-C
2
9 $2 MM (<7/8) at high-res HLA-A, -B, and
-DRB1 and low-res at HLA-C
2
(Continued )
Table 2. (Continued )
HLA Groups N
10 Matched 8/8 at low-res HLA-A, -B and -C and
high-res at HLA-DRB1
30
11 Single MM (7/8) at low-res HLA-A, -B, and -C
and high-res at HLA-DRB1
7
16 Matched 6/6 at high-res HLA-A, -B, and -DRB1
(HLA-C unknown)
6
21 Matched 6/6 at low-res HLA-A and -B and high-
res at HLA-DRB1 (HLA-C unknown)
59
§Other GVHD prophylaxis includes (N 5 4)
1. MTX 6 other (n 5 1)
2. GVHD given, not specified (n 5 2)
3. None (n 5 1)
556 Biol Blood Marrow Transplant 15:554-563, 2009K. van Besien et al.grafts (n 5 5) were excluded from analysis. Central
histology review was not performed.Study Endpoints
Outcomesanalyzed includedengraftment, acuteand
chronic graft-versus-host disease (aGVHD, cGVHD),
treatment-related mortality (TRM), relapse/progres-
sion, progression-free survival (PFS), and overall sur-
vival (OS). The incidence and stage of acute skin, liver,
and intestinal GVHDwere measured by standard crite-
ria [30]. cGVHDwasclassifiedaccording to the standard
criteria in use prior to the recent consensus statement
[31]. Lymphoma histology was classified according to
the World Health Organization (WHO) classification
[32].Theday of engraftmentwas defined as the first of 3
consecutive days on which the absolute neutrophil
count (ANC) exceeded 0.5  109/L or time to neutro-
phil count.3  109/L on 1 occasion.
TRM was defined as death within 28 days post-
transplant or death without lymphoma progression,
and summarized using the cumulative incidence esti-
mate with progression or relapse as the competing
risk. Progression was defined as progressive lymphoma
posttransplant or lymphoma recurrence. It could
follow a period of ‘‘stable’’ disease posttransplant, or
a partial or complete remission. Progression repre-
sents new or larger areas of lymphoma ($25% increase
in largest diameter) compared to the state of best post-
transplant response. Progression was summarized by
the cumulative incidence estimate with TRM as the
competing risk. For PFS, subjects were considered
treatment failures at the time of lymphoma progres-
sion or death from any cause. Subjects alive without
evidence of lymphoma progression were censored at
last follow-up and the PFS event was summarized by
a survival curve. The OS interval variable was defined
as time from the date of transplant to the date of death
or last contact and summarized by a survival curve.
A variety of HLA typing methods were utilized
over the period of study for matching donor recipient
pairs. These included serologic typing, or molecular
Table 3. Univariate Probabilities of Transplant Outcomes
among Patients Who Underwent Matched Unrelated Donor
Allogeneic Hematopoietic Stem Cell Transplant with Mye-
loablative Conditioning for NHL
Outcome event N Prob (95% CI)*
100-day mortality 283 39 (33-45)
ANC>0.5  109/L 283
@ 28 days 89 (86-93)
@ 100 days 90 (87-93)
Acute GVHD @ 100 days, grades (3-4) 281 25 (20-30)
Chronic GVHD 280
@ 1 year 27 (22-32)
@ 3 years 31 (26-37)
@ 5 years 32 (26-37)
TRM 283
@ 1 year 44 (38-49)
@ 3 years 49 (43-55)
@ 5 years 52 (45-57)
Progression/relapse 283
@ 1 year 25 (20-30)
@ 3 years 26 (21-32)
@ 5 years 26 (21-32)
PFS 283
@ 1 year 31 (26-37)
@ 3 years 25 (20-30)
@ 5 years 22 (17-28)
OS 283
@ 1 year 36 (31-42)
@ 3 years 28 (22-33)
@ 5 years 24 (19-30)
NHL indicates non-Hodgkin lymphoma; CI, confidence interval; ANC,
absolute neutrophil count; GVHD, graft-versus-host disease; TRM,
treatment-related mortality; PFS, progression-free survival, OS, overall
survival.
*Probabilities of neutrophil, acute and chronic GVHD (aGVHD,
cGVHD), TRM, and progression/relapse were calculated using the cu-
mulative incidence estimate. 100-day mortality, PFS, andOS were calcu-
lated using the Kaplan-Meier product limit estimate.
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fore reclassified as well matched, partially matched,
or mismatched according to recent criteria proposed
by Weisdorf et al. [33].Statistical Analysis
Subject-, disease-, and transplant-related variables
for subjects were described. Univariate probabilities ofPr
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Figure 1. OS and PFS after unrelateddeveloping TRM and lymphoma relapse/progression
were calculated using cumulative incidence curves to
accommodate corresponding competing risks [33].
Probabilities of OS and PFS were calculated using
Kaplan-Meier estimator [34]. Confidence intervals
(CI) were calculated with a log-transformation.
The effect of pretransplant variables on the out-
comes of TRM, lymphoma progression, PFS, and
survival after transplantation, was compared using
Cox proportional hazards model incorporating pre-
transplant variables of interest [35]. Covariates that
influenced outcomes were identified by stepwise for-
ward selection multivariate model. Any covariate with
a value of P# .05 was considered significant. The pro-
portionality assumption for Cox regression was tested
by adding a time-dependent covariate for each risk fac-
tor and each outcome. Tests indicated that all variables
met the proportional hazards assumption. Results were
expressed as relative risks (RR) or the relative rate of oc-
currence of the event. The following variables (summa-
rized in Table 1) were considered in multivariate
analyses: age at transplant, sex, Karnofsky Performance
Status (KPS) at transplant, lymphoma histology,
disease status, and chemosensitivity at transplant,
time from diagnosis to transplant, TBI-based condi-
tioning, T cell depletion, donor-recipientHLAmatch,
donor-recipient CMV status, and year of transplant.
There were no statistically significant center effects
[36]. Analyses were performed using SAS software,
version 8.2 (SAS Institute, Cary, NC).RESULTS
Patient Characteristics
Two hundred eighty-three NHL patients were
identified who received unrelated allogeneic bone
marrow transplants at 63 transplant centers between
1991 and 2004. Fifty-six percent of these transplants
occurred between 2000 and 2004. The medianrs
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donor allogeneic HCT for NHL.
Table 4. Multivariate Analysis Comparing Treatment-Re-
lated Mortality among Patients Who Underwent Matched
Unrelated Donor Allogeneic Hematopoietic Stem Cell
Transplant with Myeloablative Conditioning for NHL
Variables N
Relative
Risk (95% CI) P-Value
Age at transplant
#20 46 1.00* P†overall 5 .003
21-40 105 1.76 (0.97-3.20) .062
$40 105 2.82 (1.51-5.28) .001
Karnofsky
performance
status
$90 162 1.00*
<90 94 1.53 (1.07-2.18) .018
Histology
Follicular 52 1.00* P†overall 5 .021
DLCL/
Immunoblastic
70 1.91 (1.15-3.16) .012
Lymphoblastic/
Burkitts/
Burkitt-like
61 1.97 (1.11-3.48) .020
Mantle cell 20 2.23 (1.15-4.31) .017
Peripheral T cell 15 0.61 (0.21-1.76) .360
Others 38 1.50 (0.80-2.80) .204
CI indicates confidence interval; DLCL, diffuse large cell lymphoma;
NHL, non-Hodgkin lymphoma.
*Reference group.
†2 degrees of freedom.
Table 5. Multivariate Analysis Comparing Progression/Re-
lapse among Patients Who Underwent Matched Unrelated
Donor Allogeneic Hematopoietic Stem Cell Transplant with
Myeloablative Conditioning for NHL
Variables N
Relative
Risk (95% CI) P-Value
Disease status at transplant
Within 3 months
posttransplant*
Chemosensitive CR 67 1.00† P‡overall 5 .008
Chemosensitive PR 93 4.42 (1.46 - 13.34) .008
Chemoresistant 96 5.74 (1.90 - 17.36) .002
Histology
Follicular 52 1.00† P‡overall 5 .020
DLCL/Immunoblastic 70 1.69 (0.72-4.00) .231
Lymphoblastic/Burkitts/
Burkitt-like
61 3.53 (1.53-8.14) .003
Mantle cell 20 2.46 (0.74-8.21) .143
Peripheral T cell 15 0.37 (0.05-2.96) .349
Others 38 2.49 (1.02-6.10) .046
CI indicates confidence interval; DLCL, diffuse large cell lymphoma;
NHL, non-Hodgkin lymphoma.
*Time-dependant covariates. The effect of disease status at transplant
differs with the length of time after transplant. Patients transplanted
with chemoresistant disease had no different progression/relapse rates
than patients transplanted with chemosensitive disease, when consider-
ing time period beyond 3 months after transplant. However, when con-
sidering the first 3 months after transplant patients transplanted with
chemoresistant disease had higher rates of progression/relapse.
†Reference group.
‡2 degrees of freedom.
558 Biol Blood Marrow Transplant 15:554-563, 2009K. van Besien et al.follow-up for surviving patients is 5.1 years (0.7-12.1).
Themedian time interval between diagnosis and trans-
plant was 1.4 (range: 0.9-16) years. Patient characteris-
tics are summarized in Table 2.
The median age at the time of transplant was 37
(range: 2-65) years. Sixty-six percent of patients were
male. Twenty-two percent of patients had FL 26%
diffuse large B cell lymphoma, 24% lymphoblastic,
Burkitt’s or Burkitt-like lymphoma, 7% mantle cell
lymphoma, and 7% had peripheral T cell lymphoma.
Fourteen percent were classified as other. This group
includes patients where no specific histology was pro-
vided, but also some with rare histologies (Table 2,
footnote *). Thirty patients were reported as having
transformed lymphoma. For analysis they were catego-
rized under the histologic diagnosis at the time of trans-
formation. Only 15% of patients underwent transplant
in first complete remission and 11% in second or sub-
sequent remission. Themajority of patients were not in
remission at transplant: 49% with primary induction
failure, 15%with sensitive relapse, and 10%with resis-
tant relapse. Overall, 38% patients were chemotherapy
refractory at the time of transplant. The large majority
of patients (84%) received TBI containing regimens.
The donor grafts were non-T depleted in 72% of cases
and they were mostly bone marrow grafts. Standard
GVHD prophylaxis that is, a calcineurin inhibitor
plus methotrexate (MTX) was used in 72% of cases.
Donors were well matched in 54%, partially matched
in 39%, andmismatched in 6% of cases. Thematching
for 2 donors (1%), was unknown.Outcomes
Outcomes are summarized in Table 3. Ninety per-
cent of patients engrafted, and almost all of these had
reached an ANC of .0.5 by day 28. The overall
100-day mortality was 39%. TRM was 44% by 1
year and increased to 52% by 5 years. The cumulative
incidence of grade iii-iv aGVHD was 25% and the cu-
mulative incidence of cGVHD increased to 32% at
5 years. The risk for disease progression was 25% at
1 year, with no change in subsequent years. PFS at 1
year was 31% and decreased to 22% at 5 years. OS
was 36% at 1 year and decreased to 24% at 5 years
(Figure 1).Multivariate Analysis
Multivariate analyses for the outcomes of TRM,
relapse/progression, PFS, and OS are summarized in
Tables 4-7.
Treatment-related mortality
After adjustment for covariates the relative risk of
TRM was 3.02 for those over the age of 40 years (P\
.001) compared to patients aged 20 years or younger.
KPS of\90 was also associated with a 50% increased
risk for TRM (RR5 1.43, P5 .05). Compared to those
with FL or those with peripheral T cell lymphoma,
patients with diffuse large cell, lymphoblastic/Burkitt,
or mantle cell lymphoma had significantly worse TRM.
Table 6. Multivariate Analysis Comparing Progression-Free
Survival among PatientsWho Underwent Matched Unrelated
Donor Allogeneic Hematopoietic Stem Cell Transplant with
Myeloablative Conditioning for NHL
Variables N
Relative
Risk (95% CI) P-Value
Karnofsky performance status
$90 162 1.00*
<90 94 1.39 (1.03-1.87) .031
Histology
Follicular 52 1.00* P†overall <.001
DLCL/Immunoblastic 70 1.56 (1.02-2.39) .041
Lymphoblastic/Burkitts/
Burkitt-like
61 1.92 (1.23-2.99) .004
Mantle cell 20 2.62 (1.48-4.66) .001
Peripheral T cell 15 0.43 (0.17-1.11) .083
Others 38 1.41 (0.86-2.32) .170
Disease status at transplant
Within 3 months post
transplant‡
Chemosensitive CR 67 1.00* P§overall 5 <.001
Chemosensitive PR 93 2.13 (1.20-3.78) .010
Chemoresistant 96 3.25 (1.86-5.70) <.001
CI indicates confidence interval; DLCL, diffuse large cell lymphoma; CR,
complete remission; PR, partial remission.
*Reference group.
†4 degress of freedom.
‡Time-dependant covariates. The effect of disease status at transplant dif-
fers with the lengthof time after transplant. Patients transplantedwith che-
moresistant disease had no different progression/relapse or death rates
than patients transplanted with chemosensitive disease, when consider-
ing time period beyond 3 months after transplant. However, when con-
sidering the first 3 months after transplant patients transplanted with
chemoresistant disease had higher rates of progression/relapse or death.
§2 degrees of freedom.
Table 7. Multivariate Analysis Comparing Survival among
Patients Who Underwent Matched Unrelated Donor Alloge-
neic Hematopoietic Stem Cell Transplant with Myeloablative
Conditioning For NHL
Variables N
Relative
Risk (95% CI) P-Value
Age at transplant
#20 46 1.00* P†overall 5 .025
21-40 105 1.12 (0.73-1.74) .596
$40 105 1.72 (1.07-2.75) .025
Karnofsky performance status
$90 162 1.00*
<90 94 1.38 (1.02-1.87) .037
Histology
Follicular 52 1.00* P‡overall 5 <.001
DLCL/immunoblastic 70 1.91 (1.23-2.99) .004
Lymphoblastic/Burkitts/
Burkitt-like
61 2.25 (1.38-3.67) .001
Mantle cell 20 2.16 (1.20-3.88) .010
Peripheral T cell 15 0.44 (0.15-1.27) .128
Others 38 1.67 (0.99-2.80) .054
Disease status at transplant
Within 3 months post
transplant§
Chemosensitive CR 67 1.00* P†overall 5 <.001
Chemosensitive PR 93 1.70 (0.90-3.24) .103
Chemoresistant 96 2.99 (1.62-5.52) <.001
CI indicates confidence interval; CR, complete remission; DLCL, diffuse
large cell lymphoma; PR, partial remission; NHL, non-Hodgkin lym-
phoma.
*Reference group.
†2 degrees of freedom.
‡4 degrees of freedom.
§Time-dependent covariates. The effect of disease status at transplant dif-
ferswith the lengthof time after transplant. Patients transplantedwith che-
moresistant disease had no different death rates than patients
transplantedwith chemosensitive disease, when considering time period
beyond 3months after transplant. However, when considering the first 3
months after transplant patients transplanted with chemoresistant dis-
ease had higher rates of death.
Biol Blood Marrow Transplant 15:554-563, 2009 559Unrelated Transplantation for non-Hodgkin LymphomaLymphoma relapse/progression
The risk for disease recurrence was increased
5-fold (RR 5 5.74, P 5 .002) for those undergoing
transplant with refractory disease and 4-fold (RR 5
4.42, P 5 .008) for those undergoing transplant in
partial remission compared to those undergoing trans-
plant in complete remission. Lymphoblastic or Bur-
kitt’s histology was also associated with increased
disease recurrence (RR 5 3.53, P 5 .003).
PFS and treatment failure
PFS was adversely associated with lower perfor-
mance status, aggressive disease histology, and chemo-
therapy resistance. KPS \90 was associated with
a higher risk of treatment failure (RR 5 1.39, P 5
.03). Patients with diffuse large cell, lymphoblastic/
Burkitt’s/Burkitt-like, or mantle cell histology were
at higher risk of treatment failure than those with
follicular or peripheral T cell lymphoma. Patients in
partial remission at transplant (RR 5 2.13, P 5 .01)
or those with chemotherapy resistant disease (RR 5
3.25, P\ .001) were at higher risk of treatment failure
within 3 months of transplant.
Survival
Survival was superior for younger patients, those
with better performance status, those with FL orperipheral T cell lymphoma, and those with chemo-
therapy sensitive disease. Figure 2 shows survival
curves by disease histology. Figure 3 illustrates the
impact of KPS on survival, and Figure 4 the impact
of disease stage.
Causes of death
Two hundred ten patients died with 29% of the
deaths (29%) attributable to progressive lymphoma.
Organ failure (19%), infection (15%), pulmonary
syndrome (13%), and GVHD (12%) were the other
major causes of mortality. Relapse accounted for
39% of deaths in patients with lymphoblastic or
Burkitt’s lymphoma (P\ .01 versus all others).DISCUSSION
Multiple prospective and observational studies
have demonstrated the curative potential of sibling
transplantation in a variety of lymphoma subtypes
and have established it as a reasonable alternative to
autologous transplantation [8-14,16,17,19-23,37-39].
Our analysis is the first large-scale report on outcome
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Figure 2. OS after unrelated donor allogeneic HSC for NHL by histology.
560 Biol Blood Marrow Transplant 15:554-563, 2009K. van Besien et al.of unrelated donor transplantation in patients with
lymphoma. These patients were transplanted over
a 14-year period between 1991 and 2004. Many of
the patients had chemotherapy refractory disease and
many had a decreased performance score. Ninety per-
cent engrafted, and 26% of patients survived free of
disease for up to 5 years. Thus, unrelated donor trans-
plantation can be considered a beneficial and curative
procedure for a fraction of patients with NHL.
Disconcertingly, the TRM was as high as 50%, and
was variably caused by organ toxicity, GVHD, and in-
fections (Table 8). This is reminiscent of the very high
TRM observed in early studies of HLA-identical
transplantation for low-grade lymphoma where small
numbers of patients were reported frommultiple insti-
tutions [40]. Baseline patient and disease-related
adverse risk factors should be considered when assess-
ing candidacy for unrelated donor transplantation.
Those risk factors included the chemotherapy refrac-
tory nature of the disease and a decreased performance
status in many patients. Disease status [9,16,41,42] and
performance score [9,40,43-45] have previously been
identified as predictors of outcome. With better pa-
tient selection, it is to be expected that outcomes would
be much improved. As in previous studies, older agePr
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Figure 3. OS after unrelated donor aand, particularly, age of over 40 years was another in-
dependent predictor for outcome, because of increased
TRM associated with increasing age [8,29,40,46]. It is
likely that older patients, in part because of comorbid-
ities, are less tolerant of the intensive conditioning reg-
imens, and that they would benefit from reduced
intensity conditioning (RIC) as was recently shown
by the Seattle group [42].
The marked influence of disease histology on
TRM and on disease recurrence is also consistent
with numerous prior observations. Patients with FL
and those with peripheral T cell lymphoma had the
lowest risk of TRM and of disease recurrence. The
low recurrence rate in FL is also consistent with previ-
ous observations. A relatively low rate of TRMmortal-
ity has by many been attributed to the use of RIC
[11,47]. In registry analysis, however, the TRM of
myeloablative transplantation for FL has also de-
creased over time and is not different than that associ-
ated with reduced intensity conditioning [9,48,49].
The relatively good outcome in the small group of
15 PTCL patients, 12 of whom had recurrent or
refractory disease, is gratifying, and adds support to
emerging data on the role of allogeneic transplantation
in this otherwise difficult to treat disorder [21,50].rs
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Biol Blood Marrow Transplant 15:554-563, 2009 561Unrelated Transplantation for non-Hodgkin LymphomaHaving aggressiveB cell lymphomaswas a independent
risk factor for disease recurrence, and also for TRM.
Although disease relapse can be attributed to disease
biology, it is more difficult to understand how disease
histology could relate directly to TRM. We speculate
that patients with aggressive B cell lymphomas either
because of disease biology or more intensive prior
treatment present to transplant with a more pro-
inflammatory host milieu, markers of which have
been repeatedly shown to be associated with TRM
[51,52]. Donor matching is an increasingly important
determinant of outcome of unrelated donor transplan-
tation, particularly in patients with favorable disease
stages [2]. Because so many patients in the current
study had advanced disease, it is not surprising that
no impact of HLA typing on outcome could be
detected.
In summary, unrelated donor HCT induced long-
term survival in approximately 25% of patients with
lymphoma transplanted between 1991 and 2004. TheTable 8. Causes of Death among Patients Who Underwent
Matched Unrelated Donor Allogeneic Hematopoietic Stem
Cell Transplant with Myeloablative Conditioning For NHL
Causes of Death N eval N (%)
Number of patients 210
Primary disease 60 (29)
GVHD 25 (12)
Pulmonary syndrome 27 (13)
Infection 32 (15)
Organ failure 41 (19)
Others* 25 (12)
NHL indicates non-Hodgkin lymphoma; GVHD, graft-versus-host dis-
ease.
*Others include (N 5 25)
1. New malignancy (n 5 3)
2. Hemorrhage (n 5 11)
3. Vascular (n 5 1)
4. Acute cardiac infarct (n 5 1)
5. Failure to thrive (n 5 1)
6. TTP (n 5 1)
7. Metabolic abnormalities (n 5 1)
8. Nonbacterial thrombotic (n 5 1)
9. Status epilepticus (n51)
10. Other, not specified (n 5 4)outcomes are poor for those with refractory disease
and decreased performance status, but encouraging
in patients with FL and T cell lymphoma. It is likely
that with better patient and donor selection, improved
supportive care, and changes in conditioning and
GVHD prophylaxis, current results are superior, as
was shown in single institution studies and in registry
studies of sibling transplant for FL [42,49].Unrelated
donor transplantation should be considered a treat-
ment alternative for patients with high risk, recurrent,
or refractory lymphoma, particularly for those with
good performance status and chemotherapy sensitive
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